Analysts say the timing to promote Indian generics globally is just right as the next three years will be crucial in terms of opportunity.
A govt panel will recommend fixing retail prices of 348 drugs at weighted average price of brands with over 1% market share.
The move by All India Drug Action Network can further delay implementation of the policy that has been pending for 10 years.
Max India chairman Analjit Singh has raised his stake in the healthcare and insurance company by 2%, consolidating his holding in the diversified company to 39%.
The company is yet to get the US food and Drug Administration's approval for the generic version of the drug, valsartan.
Mitsui is buying out the stakes of IL&FS Trust Co, IDBI Trusteeship Services and Rainbow Fund, according to an application to the FIPB.
The panel of ministers tasked with the mandate to finalise the country's drug pricing policy is expected to decide the crucial policy as early as next week.
A group of ministers is finalising the National Pharmaceutical Pricing Policy, 2011, which will spell out whether the maximum retail price of 348 essential drugs should be based on the average of the three top-selling brands or cost of production.
The law ministry has favoured widening of the CCI's mandate to give it the power to vet acquisitions of local pharma cos by MNCs & foreign investors.
The Delhi HC dismissed Hoffmann-La Roche's suit accusing Cipla of infringing the Swiss company's patent for its lung cancer medicine Tarceva.
- No blogs yet have been written by the author, we’re sure the author will contribute one soon